



December 2014

Arch Therapeutics Marches Quickly Towards Expected Regulatory Approval and Commercialization for Its Multi-Billion Dollar Technology

By Paul Silver

Arch Therapeutics, Inc. (OTCQB: ARTH) is a Boston-based life sciences company that develops products to stop bleeding and control leaking during surgery and trauma care. Both bleeding and leaking are big problems for first responders and surgeons around the world, and if not well-controlled are major drivers of poor surgical outcomes, including patient mortality.

Compared with currently-available products, Arch Therapeutics is developing its first product, AC5 Surgical Hemostat Device™, to work better and with fewer side effects, and be very easy to prepare and apply, making it especially valuable in time-critical surgical and trauma applications. Both Arch and independent investigators reported results in animal liver surgery that supported AC5™ promptly stopped bleeding in animals that were on the anticoagulant heparin with a time to hemostasis (TTH) that was equivalent to the TTH of those animals not on blood thinners, representing a major differentiating feature with implications for surgery, home care and trauma.

Arch Therapeutics AC5 Surgical Hemostat Device™

Based on technologies originally developed at MIT, Arch's flagship product is composed of short chains of amino acids (called peptides) that self-assemble into sealing structures when exposed to blood or other internal body fluids. The product comes in a powered form and is mixed with water before use, making it very easy to transport, store, prepare, and use. The prepared product has the consistency of a gel such as

Purell hand sanitizer, and is transparent after application, a big benefit to surgeons.



Regulatory/Approval Pathway

Although still in the pre-clinical stage at this time, Arch is developing AC5™ as a medical device, based on known regulatory guidelines that differentiate devices, biologics, and pharmaceuticals, making its approval process far more streamlined than would be the case were it considered a new drug. The Company believes that it will be approved for sale in Europe in 2015 and hopes to be approved in the U.S. shortly thereafter.

Expected regulatory path: Medical Device

- CE Mark EU (first focus)
- PMA USA

Formal biocompatibility studies and planning clinical trial for 2014

Target Markets

Arch Therapeutics, Inc. serves the rapidly growing hemostatic agents and surgical sealants market, which is forecast to grow to over \$6 billion in 2017 from its 2013 size of \$4.5 billion.

- **Surgery:** Arch Therapeutics plans to focus on surgery markets first, where its superior technology and cost-competitiveness should translate into a quick and large market penetration.
- **Trauma:** The next likely focus of the Company's marketing efforts, the trauma market is very large and consists of civilian and military first-responders.
- **Home Use:** At some point, the product's low manufacturing cost and ease of use should allow it to compete in the home-use market, both domestically and abroad.

Funding

Historically, the Company was a collaborator and the recipient of funding from the Irish National Science Foundation. Management believes that new government funding opportunities are available, which could support R&D resources in a non-dilutive manner.

In October 2014, the Company announced that it is negotiating a potential collaboration agreement with CÚRAM Centre for Research in Medical Devices ("CÚRAM"). CÚRAM is a major new national research center being established at the National University of Ireland Galway (NUIG) in Galway, Ireland, as part of a six-year grant from the Irish government. Arch and leaders of CÚRAM have previously worked closely together on other initiatives. The Collaboration agreement would provide additional technical and financial support for the company's R&D program, including clinical and regulatory activities targeting planned CE Mark.

Completion of Significant 2014 Milestones

1. Initiate biocompatibility program
2. Show AC5™ efficacy in animals on heparin (blood thinner): Arch study
3. Confirm AC5™ efficacy in animals on heparin: Independent study
4. Select GMP manufacturers
5. Select Notified Body for EU regulatory pathway

Investment Conclusions

Arch Therapeutics' AC5™ is meeting the need for a novel product that effectively and safely stops bleeding. For investors, assuming its non-U.S. clinical trial is successful, due to its classification as a medical device, the approval process is far quicker compared to a drug which would mean a faster path to commercialization. In addition, the applications are wide, and include all types of in-patient surgery as well as home procedures especially given the animal data illustrating its effectiveness in the presence of anticoagulants (blood thinners are used by 18% of U.S. population 65 years and older), making the commercial opportunity much larger than the surgical \$4.5 billion market. Arch Therapeutics represents an attractive acquisition candidate by a major pharmaceutical company looking to capture this multi-billion dollar opportunity.

Paul Silver




Paul Silver is the Managing Director of Research at Wall Street Resources. Previously he has been in auditing with a Big Four accounting firm in New York City, a sell-side research analyst for two global investment banks in New York City including Salomon Smith Barney and UBS Paine Webber. At Salomon Smith Barney he was a member of the firm's research team covering Real Estate Investment Trusts that was consistently ranked #1 by Institutional Investor magazine. Mr. Silver has written extensively on small cap equities and is a contributing writer to numerous publications is a co-manager of the WSR High Alpha model portfolio which has resulted in a 127.39% average annualized return from inception on March 13, 2009 through December 31, 2013. For more information visit:

http://www.wallstreetresources.net/High_Alpha_Performance.aspx

Performance Update 3-13-2009 through 12-31-2013

As we close the record books for 2013, we are very pleased to report the following results.



Portfolio or Index	Value 3/13/2009	Projected Value 12/31/2009	Projected Value 12/31/2010	Projected Value 12/31/2011	Projected Value 12/31/2012	Projected Value 12/31/2013	Average Annualized Return
High Alpha Portfolio	\$100,000	\$202,259	\$459,914	\$1,045,788	\$2,377,996	\$5,407,278	127.39%
Dow Jones Industrial Average	\$100,000	\$115,295	\$137,262	\$163,415	\$194,551	\$231,620	19.05%
S&P 500	\$100,000	\$116,554	\$140,590	\$169,583	\$204,555	\$246,739	20.62%
NASDAQ	\$100,000	\$120,115	\$150,214	\$187,855	\$234,928	\$293,797	25.06%

Additional Portfolio Statistics:

High Alpha Portfolio 3/13/2009 to 12/31/2013	Open Positions	%	Closed Positions	%	Open & Closed Positions	%
Winning Trades	17/24	71%	67/87	77%	84/111	76%
Losing Trades	7/24	29%	20/87	23%	27/111	24%
Average Return	128.74%		65.27%		78.99%	
Average Annualized Return	37.80%		152.10%		127.99%	

For a complete list of every trading alert from 3/13/2009 through 12/31/2013, as well as full access to all of our premium content, sign up for your risk free trial to WSR's High Alpha Stocks at:


https://www.wallstreetresources.net/HighAlpha_Signup.aspx

WSR's Featured Companies:

Wall Street Resources is a professional research and consulting firm connecting under-followed emerging growth companies with sophisticated investors looking for emerging growth company investment ideas. Leveraging over a decade of experience analyzing micro-to-small capital companies, the principals of WSR are dedicated to providing aggressive investors with unique opportunities, while helping emerging growth companies communicate with the investment community. The following companies are WSR's current clients which support its financial publications:

Featured Companies:**Black Ridge Oil & Gas, Inc.**
OTCQB/OTCBB:ANFC

Black Ridge Oil & Gas controls over 12,000 net acres in the Bakken and Three Forks play in western North Dakota and eastern Montana. The 2013 US Geological Survey assessment estimated that there are 3.7 billion barrels of recoverable oil in the Bakken Formation and an additional 3.7 billion barrels of recoverable oil in the Three Forks Formation. At a total of 7.4 billion recoverable barrels, this represents a twofold increase from the 2008 assessment. Together with the continued advances in horizontal drilling technology, the Bakken oil play is proving to be both high-yield and sustainable.



To obtain additional information go to: <http://www.wallstreetresources.net/Ante5.aspx>

EnerJex Resources, Inc.
OTCQB:ENRJ

EnerJex Resources, Inc. is an independent exploration and production company focused on the acquisition and development of oil and natural gas properties located in the mid-continent region of the United States. The Company owns oil and gas leases covering nearly 100,000 acres in multiple prolific hydrocarbon basins located in four states including Colorado, Kansas, Nebraska, and Texas. EnerJex's operations are focused in five distinct projects where the company produces oil and natural gas from reservoirs that are characterized by long lived reserves with low production decline rates. Within these projects, the Company has identified more than 500 low-risk drilling locations. Through its large acreage footprint in the Denver-Julesburg ("DJ") Basin, EnerJex also has significant exposure to emerging oil resource plays that are being pursued by competitors on trend with the Company's properties.



To obtain additional information go to: <http://www.wallstreetresources.net/enerjex.aspx>

FieldPoint Petroleum Corp.
AMEX:FPP

The Company acquires, operates, and develops oil and gas properties located in Texas and Wyoming. FieldPoint Petroleum looks to continue expanding in Texas and Wyoming, as well as in other Rocky Mountain and mid-continent states such as Montana, North Dakota and Oklahoma. As of January 2013, the Company has varying ownership interest in approximately 300 wells located in Oklahoma, Louisiana, New Mexico, Texas and Wyoming. FPPC oil and gas production is sold on the spot market. The Company believes that, with operator's responsibility and authority, it is in a better position to control cost, safety, and work timelines, as well as other critical factors affecting the wells' economics.



To obtain additional information go to: <http://www.wallstreetresources.net/fieldpoint.aspx>

Gray Fox Petroleum Corp.
OTCQB:GFOX



Gray Fox Petroleum is an oil and gas exploration and development company focused on expanding the 135+ year tradition of Western US energy production.

Gray Fox owns a 82% interest in the 32,723-acre West Ranch Prospect, which is comprised of 22 Federal leases in the Butte Valley Oil Play Region of north-central Nevada, in Elko and White Pine Counties, 50 miles north of Ely, NV. The Company's West Ranch Prospect overlies structures and reservoir horizons similar to those that have produced a combined 50+ million barrels of oil in Nevada to date.

Gray Fox is currently developing an initial exploration work program to further assess the prospect's resource and production potential. To maximize on the Company's assets, Gray Fox has assembled a core team of management and advisory professionals with oil and gas exploration and production backgrounds, as well as business building and capital raising expertise.

To obtain additional information go to: <http://www.wallstreetresources.net/grayfox.aspx>

Liberator Medical Holdings, Inc.
OTCBB:LBMH



Liberator Medical Holdings, Inc.'s subsidiary, Liberator Medical Supply, Inc., established the Liberator brand as a leading national direct-to-consumer provider of quality medical supplies to Medicare-eligible seniors. An Exemplary Provider(TM) accredited by The Compliance Team, its unique combination of marketing, industry expertise and customer service has demonstrated success over a broad spectrum of chronic conditions. Liberator is recognized for offering a simple, reliable way to purchase medical supplies needed on a regular, ongoing, repeat-order basis, with the convenience of direct billing to Medicare and private insurance. Approximately 85% of its revenue comes from supplying products to meet the rapidly growing requirements of general medical supplies, personal mobility aids, diabetes, urological, ostomy and mastectomy patients. Liberator communicates with patients and their doctors on a regular basis regarding prescriptions and supplies. Customers may purchase by phone, mail or internet, with repeat orders confirmed with the customer and shipped when needed.

To obtain additional information go to: <http://www.wallstreetresources.net/liberator.aspx>

Midwest Energy Emissions Corp.
OTCQB:MEEC



Midwest Energy Emissions Corp. develops and employs patented and proprietary technologies to remove mercury from coal-fired power plant emissions. The U.S. Environmental Protection Agency's (EPA) Mercury and Air Toxic Standards (MATS) rule requires that all coal- and oil-fired power plants in the U.S., larger than 25 mega-watts, must remove roughly 90% of mercury from their emissions starting April 16, 2015. Midwest employs patented technology that has been shown to achieve mercury removal levels compliant with MATS at a significantly lower cost and with less operational impact than currently used methods, while preserving the marketability of fly-ash for beneficial use, a roughly \$450mm industry annually. Management estimates that mercury emissions control is a recurring \$2-\$3 billion opportunity in the U.S. annually, with further international growth expected as countries adopt mercury emissions regulations under the United Nations Minimata Convention on Mercury.

To obtain additional information go to: <http://www.wallstreetresources.net/MidwestEnergy.aspx>

Sanomedics International Holdings, Inc.
OTCQB:SIMH

Sanomedics International Holdings, Inc. (SIMH) is a medical technology holding company that focuses on game changing products, services and ideas "a place where physicians, entrepreneurs, and medical companies can work together to drive innovative technologies through concept, development, and ultimately commercialization. Sanomedics plans to grow existing business organically and through strategic acquisitions specifically relating to healthcare technology and services. SIMH operates three wholly-owned subsidiaries: Thermomedics, Biscayne Medical and SanoER.

To obtain additional information go to: <http://www.wallstreetresources.net/Sanomedics.aspx>

Stratex Oil & Gas, Inc.
OTCQB:STTX

Stratex Oil & Gas Holdings, Inc. is an independent energy company focus on the acquisition and subsequent organic exploitation and development of primarily operated crude oil properties in south and central Texas, within the prolific Eagle Ford Shale play, as well as non-operated working interests in North Dakota, Montana and Kansas. Stratex is fully committed to the creation of long term value for all of its stakeholders.

To obtain additional information go to: <http://www.wallstreetresources.net/Stratex.aspx>

Water Technologies Intl., Inc.
OTC:WTII

Water Technologies International, Inc., (WTII) is in the business of designing, manufacturing and distributing Atmospheric Water Generators (AWGs) and related products through its subsidiaries Aqua Pure International, Inc. and GR8 Water, Inc. The Company has patent pending products in water generation, air filtration, water filtration and dehumidification. WTII sells and distributes home, office and commercial AWGs units that produce drinking water, ranging from seven gallons to several thousands of gallons per day by extracting water from the air.

To obtain additional information go to: http://www.wallstreetresources.net/Water_Tech.aspx

DISCLAIMER - Wall Street Resources is an emerging growth company specialist, which publishes financial reports with respect to some of the securities that it covers and provides a newsletter and daily notes focused on micro-to-small capital companies on a subscription basis. The information contained in these publications is based upon sources, which we believe to be reliable, but is in no way warranted by us as to accuracy or completeness. The information contained herein is subject to change without notice, and we assume no responsibility to update the information in our financial publications. We, our affiliates, and any officer, director or stockholder or any member of their families may have a position in and may from time to time purchase or sell any securities discussed in our financial publications or included in our newsletters. An employee, author, officer, or a director of the firm, or its affiliates, may serve as a director for companies mentioned in our financial publications. There may be instances when fundamental, technical, and quantitative opinions may not be in concert. Our affiliates may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned on this web site.

Past performance does not guarantee future success, and an investment in the model theoretical portfolio might lose money. Dividends and commissions are not included in performance calculations. The model theoretical performance includes performance history of the model micro-capital portfolio. The theoretical performance contains many high-risk speculative stocks, which tend to be more volatile and more illiquid than larger more established companies. The theoretical performance of the model does not represent actual trading and does not reflect material economic, psychological and market factors that might have impacted the results if actual money had been invested.

While no companies pay a fee to be included in our micro-capital portfolio or newsletter, certain companies, which are published as featured companies on our website, pay a due diligence fee for participation in the Wall Street Resources' financial publication and distribution program. In compliance with Section 17(b) of the Securities Act of 1933, detailed information regarding compensation from such companies is included on the last page of such reports, is explained in the disclaimer located at <http://wallstreetresources.net/disclaimer.html>, and is listed below. Tax consequences must be carefully considered. Wall Street Resources, Inc. is a financial publisher and not a broker/dealer or registered investment advisor, and thus all trades and actual trading, decisions are made solely by the individual investor, not by Wall Street Resources, Inc. Wall Street Resources, Inc. and/or the employees of Wall Street Resources, Inc. will not be held responsible for any losses that might occur from the use of the information provided in our financial publications that might be acted upon by an investor. Changes in our theoretical portfolio and current quote prices are made as of the last trading day of each month and based upon the closed price.

Liberator Medical Holdings, Inc. - Wall Street Resources receives \$2,500 per month for investor relations services from Liberator Medical Holdings, Inc.

Blackridge Oil & Gas, Inc. f/k/a Ante5, Inc. - Wall Street Resources received a 44,000 shares of restricted common stock and received \$3,000 per month for investor relations services from Ante5, Inc. until September 2012.

Stratex Oil & Gas, Inc. - Wall Street Resources has received or expects to receive 50,000 shares of restricted common stock, a \$15,000 cash retainer and \$2,500 per month from Stratex Oil & Gas, Inc. from the company for investor relations, due diligence fees and consulting services.

FieldPoint Petroleum - Wall Street Resources is a consultant to FieldPoint was compensated with \$10,500 for services from December 2009 through December 2013.

EnerJex Resources, Inc. - Wall Street Resources received \$15,000 for research services from January of 2013 to June of 2013 from the Company.

Water Technologies Intl., Inc. - Wall Street Resources received 1,500,000 shares of restricted common stock for research coverage and investor relations services from Water Technologies Intl., Inc. from June of 2011 until February of 2014.

Gray Fox Petroleum Corp. - Wall Street Resources received a \$5,000 retainer and has received or expects to receive a \$3,000 per month in cash from the company for IR services from September of 2013 to September of 2014.

Midwest Energy Emissions Corp. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Sanomedics International Holdings, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Arch Therapeutics, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

GeoVax Labs, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Highpower Internatinal, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Inovio Pharmaceuticals, Inc. - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Stevia First Corporation - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Pulse Beverage Corporation - Wall Street Resources receives \$500 per month from a third party for financial writing and featured company exposure for the company.

Wall Street Resources, Inc. is not a broker/dealer or registered investment advisor and thus the information on this site is not intended to provide tax, legal or investment advice. The information does not constitute a solicitation of any order to buy or sell any securities. Wall Street Resources, Inc. is a financial publisher and not a broker/dealer or registered investment advisor, and thus all trades and actual trading, decisions are made solely by the individual investor, not by Wall Street Resources, Inc. Wall Street Resources, Inc. and/or the employees of Wall Street Resources, Inc. will not be held responsible for any losses that might occur from the use of the information provided by our newsletter services, or any other information related to Wall Street Resources, Inc. that might be acted upon by an investor. The information provided herein may be displayed and printed for your personal, noncommercial use only. You may not reproduce, retransmit, distribute, disseminate, sell, publish, broadcast or circulate the information to anyone, without the express written consent of Wall Street Resources, Inc.

This newsletter may contain forward-looking statements, particularly as related to pro forma financial statements, earnings estimates and business expectations, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. These forward-looking statements are only made as of the date of their release and Wall Street Resources and the companies discussed do not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Wall Street Resources, Inc. is an information provider only. We cannot control market conditions, liquidity, market shutdowns, entry and exit prices, Internet shut-downs, or fax and mail delays. All investors should only invest or trade with capital that is risk capital that they can afford to lose. You may cancel your Wall Street Resources' newsletter service at any time and receive a full, pro-rata refund for the unused portion of your subscription. If emerging growth stock investing or trading seems too risky for you, you might want to consider starting with a less aggressive form of investing, such as the regular mutual fund contributions.

For additional information contact:

Wall Street Resources

3545 SW Corporate Parkway

Palm City, FL 34990

772-219-7525 (telephone)

www.wallstreetresources.net